Background: Colorectal cancer is one of the most commonly diagnosed cancers and leading causes of malignancy-related deaths all over the world. MicroRNAs (miRNAs) can regulate more than 60% of human genes, including tumor-stimulating, and -suppressor genes. Therefore, they can promote cancer development and affect risk of malignancy. miR-92a overexpression in CRC enhances tumor proliferation, invasion, and metastasis through downregulating different pro-apoptosis proteins including Bim. This study aimed to assess the role of plasma miR-92a as non-invasive marker in CRC patients, outline correlation between plasma miR-92a and serum Bim, and determine their correlations with clinicopathological parameters in CRC and adenoma patients. Methods: A total of 54 newly diagnosed CRC patients, 15 colonic adenoma patients, and 15 age- and sex-matched control subjects were recruited in this study. Plasma miR-92a was assayed by TaqMan qRT-PCR and serum Bim was measured by ELISA. Results: Statistically significant overexpression of serum miR-92a was observed in CRC patients as compared to adenoma and control groups (p<0.001 each) and lower serum Bim in CRC patients as compared to adenoma and control groups (p=0.001, p <0.001 respectively). The ROC curve analysis showed excellent AUC for plasma miR-92a in discriminating CRC from control (AUC=0.994), and adenoma (AUC=0.993) groups with highest diagnostic performance in discriminating CRC from controls (at cutoff 1.43, sensitivity 98.1%, specificity 93.9%), and adenoma patients (at cutoff 1.78, sensitivity 92.6%, specificity 93.3%). The diagnostic performance in discriminating early from late CRC was good (at cutoff 15, AUC=0.641, sensitivity 61.2%, specificity 80%). A significant negative correlation was evident between plasma miR-92a and serum Bim both in adenoma and CRC groups (P<0.001 for both). Higher plasma miR-92a expression (r=0.275, p=0.044) and lower serum Bim (r=-0.299, p=0.028) were found to be correlated with late CRC stages. Conclusion: Circulating miR-92a and Bim could be promising, non-invasive diagnostic and prognostic biomarkers in CRC.
Zaki, A. , Fawzy, A. , Akel, S. Y , Gamal, H. and Elshimy, R. A. A (2022). Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 23(2), 723-730. doi: 10.31557/APJCP.2022.23.2.723
MLA
Zaki, A. , , Fawzy, A. , , Akel, S. Y, , Gamal, H. , and Elshimy, R. A. A. "Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer", Asian Pacific Journal of Cancer Prevention, 23, 2, 2022, 723-730. doi: 10.31557/APJCP.2022.23.2.723
HARVARD
Zaki, A., Fawzy, A., Akel, S. Y, Gamal, H., Elshimy, R. A. A (2022). 'Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer', Asian Pacific Journal of Cancer Prevention, 23(2), pp. 723-730. doi: 10.31557/APJCP.2022.23.2.723
CHICAGO
A. Zaki , A. Fawzy , S. Y Akel , H. Gamal and R. A. A Elshimy, "Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer," Asian Pacific Journal of Cancer Prevention, 23 2 (2022): 723-730, doi: 10.31557/APJCP.2022.23.2.723
VANCOUVER
Zaki, A., Fawzy, A., Akel, S. Y, Gamal, H., Elshimy, R. A. A Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 2022; 23(2): 723-730. doi: 10.31557/APJCP.2022.23.2.723
)